What is Fibronostics?
Fibronostics is at the forefront of revolutionizing diagnostics through AI-powered algorithms. The company specializes in screening, progression, and prognosis for liver and kidney diseases, alongside other chronic conditions. With a dual incorporation in Singapore and New York, Fibronostics has established a commercial presence across North America, Asia, Europe, and Latin America. As a SPRIM portfolio company, it benefits from a strong pedigree in global health innovation, research, and consulting, aiming to deliver accessible and advanced diagnostic tools.
How much funding has Fibronostics raised?
Fibronostics has raised a total of $14.5M across 2 funding rounds:
Series A
$8M
Unspecified
$6.5M
Series A (2020): $8M with participation from AT Capital and Elev8.vc
Unspecified (2022): $6.5M, investors not publicly disclosed
Key Investors in Fibronostics
AT Capital
AT Capital Group is a family office that specializes in actively managed businesses and passive financial investments, utilizing its own funds. They focus on sustainable businesses across Real Estate, Renewable Energy, Private & Structured Credit, and Public Markets, with a global presence.
Elev8.vc
Elev8.vc is an investment firm that participates in funding rounds, contributing capital to support company growth and innovation.
What's next for Fibronostics?
The recent major strategic investment signals a pivotal phase for Fibronostics, likely enabling expansion of its AI diagnostic platforms and further commercialization efforts. This infusion of capital is expected to bolster research and development, potentially leading to new diagnostic solutions and broader market penetration. Fibronostics' focus on chronic diseases positions it to address significant global health challenges, with this latest financing providing the resources to scale its impact and solidify its market leadership in AI-driven diagnostics.
See full Fibronostics company page
